Tg therapeutics inc
TGTX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
TGTX 近期報酬表現
-3.16%
Tg therapeutics inc
6.23%
同產業平均
1.02%
S&P500
與 TGTX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
LGND | Ligand pharmaceuticals inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
IBRX | Immunitybio inc | 4 分 | 5 分 | 2 分 | 1 分 | 1 分 | |
EXAS | Exact sciences corporation | 2 分 | 2 分 | 2 分 | 2 分 | 1 分 | |
ARWR | Arrowhead pharmaceuticals inc | 5 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
TXG | 10x genomics inc | 2 分 | 1 分 | 1 分 | 3 分 | 1 分 |
- LGND Ligand pharmaceuticals inc價值 4 分趨勢 3 分波段 2 分籌碼 3 分股利 1 分查看更多
TGTX 公司資訊
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.